Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adult

Wilkin TJ, McKinnon JE, A DiRienzo G, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes." J. Infect. Dis.. 2009;199(6):866-71.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Velilla PA, Shata MT, Lages CS, Ying J, Fichtenbaum CJ, Chougnet C. "Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients." AIDS Res. Hum. Retroviruses. 2008;24(1):52-61.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Rockwood N, Meintjes G, Chirehwa M, et al. "HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients." Antimicrob. Agents Chemother.. 2016;60(10):6050-9.
Rodriguez B, Lederman MM, Jiang W, et al. "Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection." AIDS. 2006;20(10):1379-89.

Africa

Safren SA, Hendriksen ES, Smeaton L, et al. "Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world." AIDS Behav. 2012;16(2):266-77.
Firnhaber C, Smeaton L, Saukila N, et al. "Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas." Int. J. Infect. Dis.. 2010;14(12):e1088-92.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Greer AE, San Ou S-, Wilson E, et al. "Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052." J. Acquir. Immune Defic. Syndr.. 2017;76(4):388-393.
Lockman S, Hughes M, Sawe F, et al. "Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial." PLoS Med.. 2012;9(6):e1001236.
Asmelash A, Zheng Y, Kaloustian KWools, et al. "Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa." BMC Infect. Dis.. 2014;14:331.
Grinsztejn B, Smeaton L, Barnett R, et al. "Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count." Antivir. Ther. (Lond.). 2011;16(7):1057-62.
Robertson K, Kopnisky K, Hakim J, et al. "Second assessment of NeuroAIDS in Africa." J. Neurovirol.. 2008;14(2):87-101.

Africa South of the Sahara

Shaffer D, Hughes MD, Sawe F, et al. "Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)." J. Acquir. Immune Defic. Syndr.. 2014;66(2):155-63.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Abbas UL, Anderson RM, Mellors JW. "Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings." J. Acquir. Immune Defic. Syndr.. 2006;41(5):632-41.
Abu-Raddad LJ, Barnabas RV, Janes H, et al. "Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?" AIDS. 2013;27(6):981-9.
Swindells S, Komarow L, Tripathy S, et al. "Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2013;17(4):532-9.
Derache A, Wallis CL, Vardhanabhuti S, Bartlett J, Kumarasamy N, Katzenstein D. "Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection." J. Infect. Dis.. 2016;213(2):250-6.
Dong BJ, Zheng Y, Hughes MD, et al. "Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women." AIDS. 2012;26(7):833-41.
Robertson K, Kumwenda J, Supparatpinyo K, et al. "A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings." J. Neurovirol.. 2011;17(5):438-47.

Pages